David is an Executive Director and CEO of GI Therapies and also a Venture Partner with Brandon Capital Partners having been a co-founder of the business in 2007. David had previously established Brandon Capital Management, the Investment Manager for three life sciences Pooled Development Funds in 1999.
Before this, David was foundation CEO of Peptech Limited. During this period Peptech went from a start-up to having R&D operations in Australia, the UK, the US and manufacturing operations in Denmark. Prior to Peptech David spent ten years with Pharmacia AB (now part of Pfizer, Inc), including five years at their head office in Sweden.
David is a director of Nanosonics Ltd (ASX:NAN) and a past president of the Australian Biotechnology Association. He has a first class Honours degree in Rural Science, a PhD in Chemical Engineering from the University of Sydney and a Masters degree in Applied Finance. David is a Fellow of Finsia, a graduate of the Australian Institute of Company Directors and a member of AusBiotech.